Search Results - "Reuss, A"

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease by Wilson, M.K., Pujade-Lauraine, E., Aoki, D., Mirza, M.R., Lorusso, D., Oza, A.M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S.-J., Ferrero, A.M., Edmondson, R.J., Wimberger, P., Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., Ochiai, K.

“…This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC),…”
Get full text

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer by Harter, Philipp, Sehouli, Jalid, Vergote, Ignace, Ferron, Gwenael, Reuss, Alexander, Meier, Werner, Greggi, Stefano, Mosgard, Berit J, Selle, Frederic, Guyon, Frédéric, Pomel, Christophe, Lécuru, Fabrice, Zang, Rongyu, Avall-Lundqvist, Elisabeth, Kim, Jae-Weon, Ponce, Jordi, Raspagliesi, Francesco, Kristensen, Gunnar, Classe, Jean-Marc, Hillemanns, Peter, Jensen, Pernille, Hasenburg, Annette, Ghaem-Maghami, Sadaf, Mirza, Mansoor R, Lund, Bente, Reinthaller, Alexander, Santaballa, Ana, Olaitan, Adeola, Hilpert, Felix, du Bois, Andreas

“…Patients with platinum-sensitive relapsed ovarian cancer who had undergone complete resection were assigned to undergo surgery and then receive chemotherapy or…”
Get full text

Novel specific microRNA biomarkers in idiopathic inflammatory bowel disease unrelated to disease activity by Lin, Jingmei, Welker, Noah C, Zhao, Zijin, Li, Yong, Zhang, Jianjun, Reuss, Sarah A, Zhang, Xinjun, Lee, Hwajeong, Liu, Yunlong, Bronner, Mary P

“…The diagnosis of idiopathic inflammatory bowel disease can be challenging. MicroRNAs (miRNAs) are small, non-coding RNAs that regulate protein synthesis…”
Get full text

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials by Mahner, S, Eulenburg, C, Staehle, A, Wegscheider, K, Reuss, A, Pujade-Lauraine, E, Harter, P, Ray-Coquard, I, Pfisterer, J, du Bois, A

“…Abstract Background and Aims Surgery followed by platinum-taxane chemotherapy is the current standard approach to treat advanced ovarian cancer. The impact of…”
Get full text

I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? by Kissling, Esther, Nunes, Baltazar, Robertson, Chris, Valenciano, Marta, Reuss, Annicka, Larrauri, Amparo, Cohen, Jean Marie, Oroszi, Beatrix, Rizzo, Caterina, Machado, Ausenda, Pitigoi, Daniela, Domegan, Lisa, Paradowska-Stankiewicz, Iwona, Buchholz, Udo, Gherasim, Alin, Daviaud, Isabelle, Horváth, Judit Krisztina, Bella, Antonino, Lupulescu, Emilia, O Donnell, Joan, Korczyńska, Monika, Moren, Alain

“…Since the 2008/9 influenza season, the I-MOVE multicentre case-control study measures influenza vaccine effectiveness (VE) against medically-attended…”
Get full text

Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15 by Valenciano, Marta, Kissling, Esther, Reuss, Annicka, Rizzo, Caterina, Gherasim, Alin, Horváth, Judit Krisztina, Domegan, Lisa, Pitigoi, Daniela, Machado, Ausenda, Paradowska-Stankiewicz, Iwona Anna, Bella, Antonino, Larrauri, Amparo, Ferenczi, Annamária, Lazar, Mihaela, Pechirra, Pedro, Korczyńska, Monika Roberta, Pozo, Francisco, Moren, Alain

“…Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a multicentre case-control study in eight European countries to…”
Get full text

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study by Trillsch, F., Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H.G., Hellriegel, M., Wimberger, P., Baumann, K., Keyver-Paik, M.D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schroeder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., du Bois, A.

“…Approximately one-third of all borderline ovarian tumours (BOT) are diagnosed in patients with child-bearing potential. Detailed information regarding their…”
Get full text

Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO by Klar, M, Hasenburg, A, Hasanov, M, Hilpert, F, Meier, W, Pfisterer, J, Pujade-Lauraine, E, Herrstedt, J, Reuss, A, du Bois, A

“…Abstract Objectives We evaluated in a large study meta-database of prospectively randomised phase III trials the prognostic factors for progression-free…”
Get full text

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13 by Kissling, E, Valenciano, M, Buchholz, U, Larrauri, A, Cohen, J M, Nunes, B, Rogalska, J, Pitigoi, D, Paradowska-Stankiewicz, I, Reuss, A, Jiménez-Jorge, S, Daviaud, I, Guiomar, R, O'Donnell, J, Necula, G, Głuchowska, M, Moren, A

“…In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a multicentre case-control study (MCCS) in seven European…”
Get full text

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR by Pfisterer, J, du Bois, A, Sehouli, J, Loibl, S, Reinartz, S, Reuß, A, Canzler, U, Belau, A, Jackisch, C, Kimmig, R, Wollschlaeger, K, Heilmann, V, Hilpert, F

“…Background: Abagovomab is a murine anti-idiotypic antibody against the antigen CA-125 which has been shown to elicit humoral and cellular immune responses…”
Get full text

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 by Heitz, F., Harter, P., Åvall-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., Colombo, N., Reinthaller, A., Vergote, I., Poveda, A., Ottevanger, P.B., Hanker, L.C., Leminen, A., Alexandre, J., Canzler, U., Sehouli, J., Herrstedt, J., Fiane, B., Merger, M., du Bois, A.

“…Surgical assessment of residual tumor provides the strongest prognostic information in advanced ovarian cancer (AOC), with the best outcome observed after…”
Get full text

Photo-physical properties of 2-(1-ethynylpyrene)-adenosine: influence of hydrogen bonding on excited state properties by Trojanowski, P, Plötner, J, Grünewald, C, Graupner, F F, Slavov, C, Reuss, A J, Braun, M, Engels, J W, Wachtveitl, J

“…The photo-physical properties of 2-(1-ethynylpyrene)-adenosine (PyA), a fluorescent probe for RNA dynamics, were examined by solvation studies. The…”
Get more information

IgG4-related sclerosing cholangitis in the absence of autoimmune pancreatitis mimicking extrahepatic cholangiocarcinoma by Lin, Jingmei, Cummings, Oscar W., Greenson, Joel K., House, Michael G., Liu, Xiuli, Nalbantoglu, ILKe, Pai, Rish, Davidson, Darell D., Reuss, Sarah A.

“…AbstractAims. IgG4-related sclerosing cholangitis in extrahepatic bile ducts in the absence of autoimmune pancreatitis (AIP) is rare and is poorly studied…”
Get full text

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study by Trillsch, F, Mahner, S, Vettorazzi, E, Woelber, L, Reuss, A, Baumann, K, Keyver-Paik, M-D, Canzler, U, Wollschlaeger, K, Forner, D, Pfisterer, J, Schroeder, W, Muenstedt, K, Richter, B, Fotopoulou, C, Schmalfeldt, B, Burges, A, Ewald-Riegler, N, de Gregorio, N, Hilpert, F, Fehm, T, Meier, W, Hillemanns, P, Hanker, L, Hasenburg, A, Strauss, H-G, Hellriegel, M, Wimberger, P, Kommoss, S, Kommoss, F, Hauptmann, S, du Bois, A

“…Background: Incomplete surgical staging is a negative prognostic factor for patients with borderline ovarian tumours (BOT). However, little is known about the…”
Get full text

Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses by Schoenfeld, N, Haas, W, Richter, E, Bauer, T, Boes, L, Castell, S, Hauer, B, Magdorf, K, Matthiessen, W, Mauch, H, Reuss, A, Schenkel, K, Ruesch-Gerdes, S, Zabel, P, Dalhoff, K, Schaberg, T, Loddenkemper, R

“…Non-tuberculous mycobacterioses comprise a group of diseases caused by mycobacteria which do not belong to the Mycobacterium (M.) tuberculosis-complex and are…”
Get more information

Estimating vaccination coverage in the absence of immunisation registers--the German experience by Siedler, A, Rieck, T, Reuss, A, Walter, D, Poggensee, G, Poethko-Muller, C, Reiter, S

“…Immunisation registers are regarded as an appropriate solution to measure vaccination coverage on a population level. In Germany, a decentralised healthcare…”
Get full text

Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study by Stamelou, M, Pilatus, U, Reuss, A, Respondek, G, Knake, S, Oertel, W.H, Höglinger, G.U

“…Abstract Introduction Recently, mutations in the COQ2 gene, encoding for an enzyme involved in coenzyme Q10 biosynthesis, have been suggested to confer…”
Get full text

Age-related prevalence of cross-reactive antibodies against influenza A(H3N2) variant virus, Germany, 2003 to 2010 by Blümel, B, Schweiger, B, Dehnert, M, Buda, S, Reuss, A, Czogiel, I, Kamtsiuris, P, Schlaud, M, Poethko-Müller, C, Thamm, M, Haas, W

“…To estimate susceptibility to the swine-origin influenza A(H3N2) variant virus (A(H3N2)v) in the German population, we investigated cross-reactive antibodies…”
Get full text

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013 by Wagner, U, Harter, P, Hilpert, F, Mahner, S, Reuß, A, du Bois, A, Petru, E, Meier, W, Ortner, P, König, K, Lindel, K, Grab, D, Piso, P, Ortmann, O, Runnebaum, I, Pfisterer, J, Lüftner, D, Frickhofen, N, Grünwald, F, Maier, B O, Diebold, J, Hauptmann, S, Kommoss, F, Emons, G, Radeleff, B, Gebhardt, M, Arnold, N, Calaminus, G, Weisse, I, Weis, J, Sehouli, J, Fink, D, Burges, A, Hasenburg, A, Eggert, C

Get full text

Symptoms and adverse effects with chemotherapy ± bevacizumab for platinum-resistant recurrent ovarian cancer: Analysis of the phase III AURELIA trial by Fabbro, M, Rubio, M. Jesus, Reuss, A, Rosenberg, P, Panici, P. Benedetti, Vuylsteke, P, Witteveen, P, Zagouri, F, Pujade-Lauraine, E

Get full text